Tech Guru
Long/short equity, biotech, healthcare, tech

Rockwell Medical: Short Thesis Has Played Out... Time To Re-Examine

With shares of Rockwell Medical (NASDAQ:RMTI) down 50% YTD, and with short interest down to 8% of float, I believe that the short thesis has finally lost its footing. Rockwell has bounced somewhat from its low of $3.16 on March 20th, but is well off the 52-week high of $10.70 in June of 2012. This discounted price offers investors a low entry point going into the release of Phase III data expected next month.

Rockwell is a biopharmaceutical company focusing on products for patients on dialysis, especially those patients with end-stage renal disease (ESRD), chronic kidney disease, and iron deficiency anemia. The company already has a $50 million per year business selling dialysis products, and currently has an...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details